ETFIQData as of Nov 19, 2026. · etfiq.com/funds/ffty

FFTY Fact Sheet: CapForce IBD 50 ETF

Share
$27.41
close, Nov 20, 2026

Over the year to Nov 19, 2026, FFTY returned −17.5% in total and charged 0.80% a year.

1-year total return
−14.9%
to Nov 20, 2026
Expense ratio
0.80%
a year
Net flow, since Apr 2026
−$5.9m
monthly N-PORT basis to Jul 31, 2026

Growth of $10,000, 1 year

FFTY $8,250 −17.5% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.

Returns

WindowTotal return
1 month−17.8%
3 months−25.7%
Year to date−21.3%
1 year−14.9%
3 years+24.9%
5 years−42.6%

Total return, distributions reinvested, each window to Nov 20, 2026.

Ten largest positions

HoldingWeight
Kiniksa Pharmaceuticals Intern4.24%
Guardant Health Inc3.83%
Travere Therapeutics Inc3.54%
TG Therapeutics Inc3.52%
Enova International Inc3.49%
Liquidia Corp3.44%
Okeanis Eco Tankers Corp3.26%
Oscar Health Inc3.23%
Sezzle Inc3.16%
Carpenter Technology Corp3.15%

FFTY top ten by weight, 34.9% of the fund, of its 50 equity positions, from the holdings filed for Jul 31, 2026.

Facts

Equity fund · First traded Apr 9, 2015 · Benchmark Its own holdings, as of Jul 31, 2026

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, FFTY Fact Sheet: CapForce IBD 50 ETF. Data as of Nov 19, 2026. https://etfiq.com/funds/ffty/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/ffty.